HDAC1 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat (suberoylanilide hydroxamic acid) targets class I HDAC1/2/3 and HDAC6 from class II, at nanomolar concentrations, and was FDA-approved for the treatment of cutaneous T-cell lymphoma (CTCL) in 2006 [85,86].